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a b s t r a c t
Acute heart failure (AHF) is a potentially life-threatening clinical syndrome, usually requir-
ing hospital admission. Often the syndrome is characterized by congestion, and is associat-
ed with long hospital admissions and high risk of readmission and further healthcare
expenditure. Despite a limited evidence-base, diuretics remain the ﬁrst-line treatment
for congestion. Loop diuretics are typically the ﬁrst-line diuretic strategy with some evidence
that initial treatment with continuous infusion or boluses of high-dose loop diuretic is
superior to an initial lower dose strategy. In patients who have impaired responsiveness to
diuretics, the addition of an oral thiazide or thiazide-like diuretic to induce sequential
nephron blockade can be beneﬁcial. The use of intravenous low-dose dopamine is no longer
supported in heart failure patients with preserved systolic blood pressure and its use to
assist diuresis in patients with low systolic blood pressures requires further study. Mechan-
ical ultraﬁltration has been used to treat patients with heart failure and ﬂuid retention, but
the evidence-base is not robust, and its place in clinical practice is yet to be established.
Several novel pharmacological agents remain under investigation.
# 2015 Cardiological Society of India. Published by Elsevier, a division of Reed Elsevier
India, Pvt. Ltd. All rights reserved.
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Acute heart failure (AHF) is a potentially life-threatening clinical
syndrome, usually requiring hospital admission. The syndrome
is heterogenous, but the largest group of patients is those who
develop peripheral andpulmonary congestionoverdays or weeks
prior to hospitalization. AHF can occur de novo, or can occur in
patients with chronic heart failure. In extreme cases, cardiogenic
shock may be present, with symptoms and signs of poor organ
perfusion due to low cardiac output and low blood pressure.* Corresponding author.
E-mail addresses: a.vazir@imperial.ac.uk (A. Vazir), m.cowie@impe
Abbreviations: HF, heart failure; AHF, acute heart failure; UF, ultraﬁ
http://dx.doi.org/10.1016/j.ihj.2015.10.386
0019-4832/# 2015 Cardiological Society of India. Published by ElsevierAlthough there is some variation internationally in the
duration of hospitalization with AHF, in many countries,
patients are admitted for at least 1 week, with an inpatient
mortality of 5–10%, and up to 25% are readmitted within a
month of discharge.1 With the aging population, the burden of
heart failure (HF) on health services is expected to rise, with
increasing healthcare expenditure and activity.
The management of AHF has remained largely unchanged
over the past 20 years. Across Europe, a quarter of patients
hospitalized because of worsening HF have signs of inade-
quate decongestion at the time of discharge,2 and this isrial.ac.uk (M.R. Cowie).
ltration.
, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.
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prognosis.3 Furthermore, almost a third of patients hospital-
ized with HF with congestion have worsening renal function
and have an impaired response to diuretics. Such patients
frequently have more advanced HF, characterized by even
longer lengths of hospital stay, more frequent readmissions,
and high degree of morbidity and mortality compared to
patients who are sensitive to diuretics.4,5 Clinical management
is challenging and variable, partially due to the lack of a robust
evidence-base on which to base treatment decisions.6
Congestion not only has a signiﬁcant effect on symptoms
and quality of life, but is also associated with cardiac, renal, and
liver injury, which are in turn associated with worse clinical
outcomes.7 Rapid relief of congestion is increasingly recognized
as an important therapeutic target, not only to improve
symptoms, but also to improve prognosis, reduce hospital
length of stay, and to contain costs to the healthcare system.8
In this review, we highlight and discuss the appropriate
management of congestion in patients with heart failure
based on the (limited) evidence-base for diuretics and other
pharmacological and nonpharmacological strategies currently
available. Further research is urgently needed to optimize the
outcome for patients, and to ensure best treatment at a
sustainable cost to the healthcare system.
2. Decongestion with diuretics
The type, mechanism of action, and use of diuretics and their
common side effects are summarized in Table 1. The clinical
evidence for the efﬁcacy of diuretics in reducing the symptoms
of heart failure is based on clinical experience and relatively
small-randomized studies. Most clinical practice guidelines on
the management of heart failure have given diuretic therapy a
'Class I' recommendation (evidence and/or general agreement
that a given treatment or procedure is beneﬁcial, useful, or
effective'), with consensus that diuretics help relieve symptoms
of congestion in patients presenting with ﬂuid retention.9,10
In the most recent European guidelines on heart failure,10
diuretics are recommended for the relief of dyspnea and
edema in patients with signs and symptoms of congestion,
irrespective of left ventricular ejection fraction, with the stated
aim of achieving and maintaining euvolemia with the lowest
achievable dose of diuretic. It is acknowledged that the dose
must be adjusted, particularly after restoration of 'dry body
weight', to avoid the risk of intravascular volume depletion
and dehydration, which can lead to hypotension, renal
dysfunction, and the inability to introduce disease-modifying
therapies, such as angiotensin-converting enzyme inhibitors,
beta-blockers, and mineralocorticoid receptor antagonists.
2.1. Placebo-controlled trials of diuretics
Placebo-controlled randomized trials of diuretic therapy for the
treatment of heart failure are limited to studies that include
small number of patients (ranging from 3 to 247 patients). All of
these studies reported that diuretics signiﬁcantly improved
symptoms in heart failure.15–17 None was powered to estimate
the effect on mortality, but a meta-analysis of three short-term
studies (follow-up ranging from 1 to 12 months) reportingmortality suggested a 75% relative mortality reduction [95% CI
16–93% p = 0.03]; the number of deaths was low (12 in the
placebo group and 3 in the diuretic group), and the majority of
the patients within the meta-analysis were unlikely to have met
the contemporary deﬁnition of AHF.18
2.2. Trials of thiazide versus loop diuretic
Several small studies suggest that loop diuretics are more
effective than thiazides alone in the management of HF.17,19,20
Furthermore, thiazides are also more likely to result in
electrolyte abnormalities, such as hypokalemia and hypona-
tremia.11,17 Thiazides as sole diuretic agents have a less abrupt
onset and longer duration of action than loop diuretics.21
2.3. Dose of loop diuretic
The Diuretic Optimization Strategies Evaluation (DOSE) trial is
the largest prospective, double-blind, randomized trial to
evaluate initial diuretic strategies in patients with acute heart
failure.22 Using a 2  2 factorial design, the DOSE trial
randomized 308 patients with acute heart failure to IV
furosemide given as twice-daily boluses or continuous infu-
sion, and to either a low-dose strategy (IV dose numerically
equivalent to the patient's oral dose) or a high-dose strategy
(2.5 times oral dose given intravenously), with speciﬁed dose
adjustments permitted after the ﬁrst 48 h.
There was no signiﬁcant difference in either of the co-
primary endpoints of global assessment of symptoms, or
change in serum creatinine over 72 h, with diuretic adminis-
tration by bolus or continuous infusion or with a low-versus a
high-dose strategy. However, patients randomized to the
higher dose strategy had a more favorable outcome with
regard to several secondary measures, including relief of
dyspnea ( p = 0.04), reduction in weight (p = 0.01), and net ﬂuid
loss (p = 0.01), albeit with a greater risk of serum creatinine
increasing by >0.3 mg/dL within 72 h (23% versus 14%,
p = 0.04). There was no difference in length of initial hospital
stay, or in days alive and out of hospital at day 60.
The trial data therefore suggest that a strategy of using
higher doses of diuretics on admission to hospital with AHF is
likely to more rapidly control ﬂuid retention and relieve
symptoms at the cost of a slightly higher risk of renal
dysfunction. Such a strategy does not, however, appear to
affect initial length of stay in hospital or the readmission rate.
Importantly, the DOSE trial22 demonstrated that there was no
difference between giving diuretics as a continuous infusion
versus boluses.
2.4. Decongestion with hypertronic saline to facilitate
effect of loop diuretics
A single group has reported several randomized single-blind
studies that demonstrate that the combination of hypertronic
saline infusion (150 ml of 3% NaCl) with a furosemide 250 mg
infusion is superior to furosemide infusion alone in terms of
increasing diuresis and serum sodium levels, and in reducing
the length of hospital stay. Mortality (12.9% versus 23.8%;
p < 0.0001) and readmission rate (18.5% versus 34.2%;
p < 0.0001) were both reported to be reduced over a median
Table 1. Type and mechanism of action of diuretics for
decongestion and their common side effects.
Types of diuretics
Loop Diuretics (furosemide, bumetanide, torasemide,
ethacrynic acid)
 Act on the ascending limb of the loop of Henle, block-
ing the reabsorption of up to 20–30% of ﬁltered sodium
by inhibiting the sodium, potassium, and chloride co-
transporter.
 Rapid onset of action (minutes when given intrave-
nously and 30 minutes when given orally). Short half-
life, and therefore, given several times per day.
 The drug must be delivered to the lumen of the neph-
ron and is thus dependent on glomerular ﬁltration
being sufﬁciently preserved.
 Oral bumetanide has higher bioavailability, so may be
more useful than oral furosemide in patients with
marked ﬂuid retention or gut absorption problems.
 Bumetanide is more potent than furosemide with 1:40
dose equivalence. Torasemide has a longer half-life
(3–4 h), and therefore, can be given less frequently
than furosemide or bumetanide.
 Bumetanide and torasemide undergo hepatic elimina-
tion, as opposed to furosemide, which undergoes renal
elimination, and therefore, the latter is likely to accu-
mulate with renal impairment.
 Can cause changes in systemic hemodynamics that
are initially unrelated to the degree and extent of
natriuresis that they induce. Short-term administra-
tion of furosemide leads to a rapid increase in venous
capacitance and a decline in cardiac ﬁlling pressure,
coincident with a rise in plasma renin activity.
Thiazide and Thiazide-like diuretics (hydrochlorothiazide,
bendroﬂumethiazide, or the 'thiazide-like' metolazone)

Thiazide diuretics act on the distal tubule, where they
inhibit sodium and chloride reabsorption, and block
10–15% of sodium reabsorption.
 They cause a slower onset (1–2 h) and more prolonged
(12–24 h) but milder diuretic effect compared to a loop
diuretic. Rebound sodium reabsorption is unlikely to
occur.
 Despite thiazide diuretic having a less potent diuretic
effect, their long duration of action allows a similar
degree of sodium excretion to occur throughout a
24-hour period as compared to a loop diuretic.11
 Thiazides are more likely to result in hypokalemia and
nocturia as they have a longer duration of action.
 Thiazides on their own are largely ineffective if glo-
merular ﬁltration rate is below 30 ml/min, but they
may be useful in combination with a loop diuretic in
patients who have refractory edema.
 Metolazone acts like a thiazide, but in addition it acts
on the proximal tubule where 60–70% of sodium is
reabsorbed. Therefore, metolozone can result in a pro-
found diuresis when combined with a loop diuretic. It
appears to be effective even in moderate renal
dysfunction.12 Such combination usage is typically
only required for a few days in most cases of resistant
ﬂuid retention.
Directly acting potassium-sparing diuretics (amiloride and
triamterene)
 Potassium-sparing diuretics (such as amiloride) pro-
duce a mild diuretic effect by blocking the sodium/
potassium exchange pump in the distal tubule. This
exchanger is highly active in patients with HF who are
on the combination of a loop and thiazide diuretic.
 As they have a weak diuretic effect, they are mainly
used in combination with thiazide or loop diuretics to
prevent hypokalemia,13 as they appear to be more
effective than potassium replacement.14 There is a risk
of hyperkalemia, particularly in patients with renal
dysfunction.
Mineralocorticoid receptor antagonists (spironolactone,
canrenoate, and eplerenone)
 Aldosterone (mineralocorticoid) receptor antagonists
are mainly used at low dose as neuro-hormonal block-
ers, for prognostic beneﬁt, rather than as diuretics per
se.
 However, in patients with right-sided heart failure,
liver impairment, and ascites, characterized by very
high circulating levels of aldosterone, higher doses of
spironolactone (typically, 200–400 mg/day) are often
used for their diuretic effect.
Common side effects of diuretics
 Hypokalemia with loop and thiazides.
 Hyperkalemia with potassium sparing diuretics.
 Hyponatremia more frequent with thiazides than loop.
 Impaired glucose metabolism with loop and thiazides.
 Oto-toxicity with high-dose loop.
 Acute Gout with loop and thiazide.
 Activation of Renin Angiotensin Aldosterone System
and sympathetic nervous system leading to progres-
sion of LV dysfunction.
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is expansion of intravascular volume, improved renal blood
ﬂow, and shift of ﬂuid from the interstitium into the
circulating volume.24 This method of increasing diuresis has
not been endorsed by international guidelines and requires
replication in other centers and in double-blind studies.
3. Impaired diuretic responsiveness
Impaired diuretic response, also known as ‘‘diuretic resis-
tance,’’ is reported in up to a third of heart failure patients
hospitalized with worsening symptoms25 and is associated
with a poor prognosis.26 There is no accepted deﬁnition of
impaired diuretic response, but it is generally taken to be
present when higher doses of diuretics are needed to gain a
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patient, or when the diuretic response is either diminished or
lost before the therapeutic goal is reached. Recently, metrics of
diuretic response have been suggested, such as weight loss per
unit of 40 mg of furosemide (or equivalent)5 or net ﬂuid loss per
milligram of loop diuretic (40 mg of furosemide or equivalent),4
but the clinical utility of such metrics requires prospective
validation.
Mechanisms that may be involved in an impaired diuretic
response are illustrated in Fig. 1, and include:
 Decreased drug bioavailability: increased peripheral and bowel
wall edema, leading to reduced absorption of the diuretic, in
particular with oral furosemide.27,28
 Reduced glomerular ﬁltration rate (GFR): may occur secondary
to a reduced renal perfusion due to low cardiac output and/
or venous congestion. Chronic kidney disease, or acute
kidney injury, can also prevent diuretics exerting their
beneﬁcial effects. For example, furosemide has to be
secreted by the organic acid transporter in the proximal
tubule to reach its site of action29; reduced GFR can,
therefore, reduce delivery or reduce active secretion of loop
diuretics.
 Excessive sodium uptake in the proximal tubule and the loop
of Henle: may occur secondary to the following mecha-
nisms:
 Excessive neuro-hormonal activation (renin-angiotensin
system).
 The presence of the braking phenomenon: occurs in the
period between boluses of loop diuretic, when there is no
diuretic in the proximal tubule or at the loop of Henle,
leading to rebound excessive sodium reabsorption at both
the proximal tubule and loop of Henle.Fig. 1 – Summary of mechanism that can le Excessive sodium intake can also lead to diuretic resis-
tance due to excessive sodium uptake in the proximal
tubule.
 Renal adaptation: chronic diuretic use results in increased
delivery of sodium to the distal convoluted tubule, which
consequently hypertrophies 30, and can, therefore, retain
more sodium (and water) than a diuretic naïve patient.
 Excessive sodium and water retention in the distal nephron and
collecting ducts may occur secondary to excessive aldoste-
rone- and vasopressin-mediated sodium and water reten-
tion, respectively
 Drug interaction: nonsteroidal anti-inﬂammatory drugs,
steroids, or pioglitazone can reduce the effect of diuretics
 Pseudoresistance: poor compliance with diuretics can be
misinterpreted as diuretic resistance. A good clinical history
can help identify this, as can discussions with the patient's
family or carer.
4. Strategies for decongestion in acute heart
failure patients with impaired diuretic
responsiveness
Several strategies can be employed to aid decongestion of
patients with acute heart failure manifesting impaired diuretic
responsiveness. These include diuretic and nondiuretic
strategies.
4.1. Diuretic strategies for decongestion
(1) Changing the route of administration from oral to
intravenous (thus overcoming bioavailability issues).ad to impaired diuretic responsiveness.
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tent bolus injections (in our experience, this produces only
a minor effect).
(3) Using higher doses of intravenous loop diuretics to
increase dose reaching the tubules, particularly when
GFR is poor.
(4) Sequential nephron blockade by using a combination of
diuretics,31,32 such as metolazone or bendroﬂumethiazide,
in addition to a loop diuretic. This approach requires
particularly close monitoring as it can lead to marked
electrolyte disturbance, hypotension, dehydration, and
worsening renal function.
(5) Restricting excessive dietary sodium and ﬂuid intake can
also help reduce diuretic resistance by reducing the sodium
and ﬂuid load arriving at the nephron. This strategy can be
unpleasant for patients, and in our experience it is unusual
for a patient to be able to tolerate less than 1.5litres of ﬂuid
intake daily for more than a few days.
4.2. Nondiuretic strategies for decongestion
(1) Renal dose dopamine
Dopamine has a dose-dependent mechanism of action. At
doses of 2–3 mg/kg/min ('renal dose dopamine') the drug acts
on peripheral dopaminergic receptors (DA1 and DA2) resulting
in vasodilation in the renal, coronary, splanchnic, and cerebral
circulations. At doses of 3–5 mg/kg/min, it acts as a b-agonist,
and at higher doses (5–15 mg/kg/min), it acts also as an
a-agonist inducing peripheral vasoconstriction.10 The exact
mechanism through which dopamine increases renal blood
ﬂow remains debated, but is likely to be related to an increase
in cardiac output33 and renal and peripheral vasodilation.34
Two recent trials of dopamine in AHF have showed that
there was no added beneﬁt with the addition of dopamine to
standard therapy with high-dose diuretics. In both trials,
patients with AHF had preserved systolic blood pressure. The
DAD-HF II trial35 included 161 patients with AHF with mean
systolic blood pressures of 157  28 mmHg. This trial was
stopped early due to a high incidence of tachycardia and the
lack of beneﬁt with low-dose dopamine given at 5 mcg/kg/min
with respect to 60-day or 1-year mortality, hospitalization for
HF, or overall change in dyspnea score. In the ROSE-AHF trial,36
AHF with median systolic blood pressures of 114 (104–127)
mmHg and low-dose dopamine at 2 mcg/kg/min did not
signiﬁcantly increase cumulative urine output or improve
cystatin C levels at 72 h. Furthermore, there were no signiﬁcant
differences between secondary endpoints such as heart failure
rehospitalization rate, death, or adverse events at 60 days. The
incidence of tachycardia was higher in the dopamine group.
Thus on the basis of current data, there is no role for the use of
dopamine in nonhypotensive patients with AHF.
The role for low-dose dopamine in AHF with hypotension, in
the absence of cardiogenic shock, merits further study. In our
own clinical practice, we do use renal dose dopamine in
congested patients with systolic BP of 80–100 mmHg to aid
decongestion in patients manifesting impaired diuretic respon-
siveness. In some patients, a temporary reduction in neurohor-
monal antagonists (such as ACE inhibitors or aldosterone
antagonists) may lead to an increase in blood pressure and
improved diuretic responsiveness. Once congestion has beencontrolled, these agents can be reintroduced prior to discharge,
provided close monitoring of clinical status and renal function
and electrolytes is possible.
(2) Ultraﬁltration
Acute decompensated heart failure patients with refractory
edema unresponsive to diuretic therapy may be considered for
ultraﬁltration (UF). This technique is very effective at removing
plasma ﬂuid from blood across a semipermeable membrane
that contains small holes that permit small molecules, such as
water and solutes, to pass through the membrane along its
pressure gradient to the ultraﬁltrate ﬂuid. Ultraﬁltration is
different to dialysis, in which larger sized molecules (e.g. toxins,
lactate) diffuse through a semi-permeable membrane down the
solute's concentration gradient into the dialysate ﬂuid.
The recent development of veno-venous peripheral UF with
devices that focus on UF alone has positioned UF as a potential
alternative to loop diuretics in AHF in cardiological practice.37
Small studies suggest that UF improves pulmonary and
peripheral edema, lung function, and hemodynamics without
adverse effects on renal function.38,39 UF can remove ﬂuid
relatively rapidly, at rates of up to 400 ml/h, but in practice,
200–300 ml/h is considered adequate. Lower rates may be used
if there is signiﬁcant right ventricular disease or pulmonary
arterial hypertension. The ﬂuid removal rate is reevaluated
using clinical assessment and serial hematocrit measure-
ments to ensure adequate vascular compartment reﬁll.39,40
In randomized trials, the typical treatment period has been
24 h, but UF membranes can last up to 72 h with care.
There are two key trials of UF in patients with AHF. The ﬁrst
trial was the Ultraﬁltration versus Intravenous Diuretics for
patients hospitalized for acutely decompensated heart failure
(UNLOAD) trial,38 which enrolled 200 patients with AHF, and
randomized patients to either UF or loop diuretic therapy
within 24 h of hospitalization. The co-primary endpoints of the
UNLOAD trial were weight loss and dyspnea relief at 48 h. The
UF group had greater weight loss (5.0  3.1 kg vs. 3.1  3.5 kg;
p < 0.001), but there was no difference in the patient-reported
outcome of dyspnea despite the trial being unblinded. Patients
with UF also had lower rates of rehospitalization for HF
compared with diuretic therapy (16 of 86 UF patients vs. 28 of
87 usual care patients; p < 0.04). There was signiﬁcantly less
hypokalemia and also no difference in serum creatinine with
UF compared with diuretics. The second trial was the
Effectiveness of Ultraﬁltration in Treating People With Acute
Decompensated Heart Failure and Cardio-renal Syndrome
(CARESS-HF) study.41 This trial recruited 198 patients with
AHF, worsened renal function and persistent volume overload,
and randomized them to a strategy of UF or a stepped
pharmacological strategy (escalating doses and combinations
of diuretics) with a primary endpoint of the change in serum
creatinine and change in weight at 96 h. This trial showed that
UF at a removal rate of 200 ml/h of ﬂuid was inferior to stepped
pharmacological therapy for the primary endpoint, owing to
an increase in creatinine level at 96 h (20.3  61.9 vs 3.5
 46.9 mmol/l; p = 0.003). There was no difference in weight
between the UF and stepped pharmacological therapy at 96 h,
with a mean of 5.5 kg weight loss in both groups. UF was
associated with a higher rate of adverse events related to
hypotension (or ﬁlter) problems.
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required to assess the exact role of UF in AHF. Currently, UF is
reserved for congested patients unresponsive to high-dose
diuretics, typically in specialist centers.10
In our experience, patients who are unsuitable candidates
for UF include patients with the following features, such as
poor venous access, severely impaired right ventricular
function, cardiogenic shock, and patients with advanced renal
disease in whom renal replacement therapy with hemoﬁltra-
tion would be more appropriate.
(3) Aquaretics
Vasopressin 2 receptor antagonists, such as tolvaptan, may
promote an aquaresis by blocking the effects of vasopressin on
the vasopressin 2 receptors located in the collecting ducts, thus
blocking the resorption of free water as urine passes through the
collecting ducts. This promotes water clearance without having
an effect on sodium balance. In the Efﬁcacy of Vasopressin
Antagonism in Heart Failure Outcome Study with Tolvaptan
(EVEREST) trial, involving over 4100 patients with AHF,
tolvaptan at a dose of 30 mg once per day for a minimum of
60 days had no effect on total mortality or HF hospitalization
when compared to placebo.42,43 However, tolvaptan did
signiﬁcantly improve hyponatremia in the patients with a
baseline serum sodium of less than 134 mmol/l (sodium
increased by 5.40 mmol/l at day 7 or discharge, compared with
an increase of only 1.85 mmol/l in the placebo group (p < 0.001))
and edema score at day 7 (p < 0.003, with 74% of tolvaptan
patients reporting an improvement in pedal edema by at least 2
grades compared with 70% of placebo patients). The effect on
serum sodium was maintained throughout a maximum of 40
weeks of treatment.
(4) Adenosine antagonists
Adenosine antagonists can potentially increase glomerular
ﬁltration, and enhance the diuretic effect of diuretic drugs.
Despite promising early phase data, the placebo-controlled
randomized study of the selective A1 adenosine receptor
antagonist rolofylline for patients hospitalized with acute
decompensated heart failure and volume overload to assess
treatment effect on congestion and renal function (PROTECT)
trial, involving 2033 patients with heart failure and renal
dysfunction, reported that this adenosine antagonist did not
have any beneﬁcial effects, and was associated with an
increased risk of seizures.44
(5) Other alternative strategies and strategies under
investigation
Several alternative agents may also be helpful in improving
responsiveness to diuretics. These include glucocorticoids,
levosimendan, ularitide and serelaxin, and other agents under
investigation.
Glucocorticoids may promote diuresis and protect renal
function in patients with AHF. Liu and colleagues reported the
effects of prednisolone (1 mg/kg/day or 60 mg/day) given over
4 weeks (followed by a tapering-off regimen) in patients with
diuretic-resistant AHF with mean furosemide dose of 212
 25 mg/day in addition to a thiazide and spironolactone in
an unblended uncontrolled study of 13 patients.45 They
reported an improved diuresis after a 3–4 day lag period,weight loss (9.4  3 Kg), and improved renal function with a
fall in serum creatinine (55  49 mmol/l) over a median of 20
(11–40) days. The proposed mechanism of action of gluco-
corticoids includes increased expression of natriuretic pep-
tide receptor-A (NPR-A) in the kidney and the hypothalamus,
which appear to be reduced in patients with heart failure,46
and also increasing renal blood ﬂow through dilatation of the
renal vasculature via increased renal prostaglandin, nitric
oxide, and dopamine production.47 Finally, as anti-inﬂam-
matory agents, glucocorticoids may play a disease-modifying
role in cardio-renal syndrome.
Subsequently, an open-label randomized controlled study
assessing the effects of prednisolone on outcomes compared
to standard care was designed.48 This study was stopped early
due to slow site initiation and poor recruitment due to the
reluctance of patients to take glucocorticoids. The results in
102 patients with AHF randomized to receive glucocorticoids
or standard treatment included an improvement in renal
function at 7 days (serum creatinine 0.14 versus 0.02 mg/dL
( p < 0.05)) and improved symptoms. Thirty-day survival was
better in the group receiving glucocorticoids compared to
standard care; however, the number of deaths was low (3 deaths
in glucocorticoid vs. 10 deaths in standard treatment group,
p < 0.05). Further research is needed to conﬁrm whether
glucocorticoids may be beneﬁcial in this setting.
Levosimendan, an inodilator, was studied in patients
presenting with AHF in the REVIVE studies. These showed
that levosimendan when given intravenously with a loading
dose and 24-hour infusion, patients with AHF as had improved
renal function and improved responsiveness to diuretics
leading to rapid relief of symptoms.49 However, there was
increased risk of arrhythmia and hypotension. In our clinical
practice, we use levosimendan by giving the drug without a
loading dose and starting with low doses, such as 0.05 mcg/kg/
min, and given over 24–72 h, although this method of delivery
and also its use is not licensed.
Ularitide, a human endogenous natriuretic peptide
expressed in the kidney, which induces natriuresis and
diuresis by binding to speciﬁc natriuretic peptide receptor, is
being investigated in patients with acute heart failure in the
TRUE-AHF trial (NCT01661634).
In the RELAX-AHF trial, serelaxin, a human recombinant of
the vasodilator relaxin, showed no signiﬁcant effect on
diuretic response, but it did have beneﬁcial effects in
preventing organ damage in patients with acute heart failure
who were diuretic resistant.7,50 Further studies are ongoing.
The drug is not licensed.
There are several other agents under investigation, which
could have a role in aiding decongestion of patient presenting
with acute heart failure. The ATOMIC-HF trial, a multi-center
phase 2, dose-ﬁnding study assessing the effects of Omecamtiv
Mercabil, a Cardiac Myosin activator, in patients presenting with
acute heart failure, was presented at the 2013 European Society
of Cardiology late breaking trials session. This study showed that
Omecamtiv Mercabil improved dyspnea scores when higher
doses were used compared to placebo; however, Omecamtiv
Mecarbil did not signiﬁcantly improve overall dyspnea scores,
the primary endpoint of the study. Another such agent under
investigation is TRV027, a selective angiotensin receptor type 1
blocker, leading to both vasodilatation and improved cardiac
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 6 1 – s 6 8 S67performance. Its safety and efﬁcacy is being evaluated in the
phase 2b study called BLAST-AHF (NCT01966601).
5. Conclusions
Diuretics are the mainstay of ﬁrst-line therapy in the
decongestion of patients presenting with acute heart failure,
leading to rapid relief of the symptoms of congestion.
Although the evidence-base is weak, international guidelines
have endorsed their use and they are likely to remain key to
clinical management for the foreseeable future.
The initial decongestion strategy is likely to be a loop
diuretic, such as intravenous furosemide, with the evidence
suggesting that an initial 'high-dose' strategy either by twice-
daily bolus injection or by continuous infusion is likely to be
more successful than an initial lower doses followed by a
'ramped' approach. In cases of impaired responsiveness to
loop diuretics, adding a thiazide or thiazide-like diuretic can
enhance diuresis, although close monitoring of ﬂuid balance
and electrolytes is necessary. This strategy can also be useful
in patients with signiﬁcant renal dysfunction.
Low-dose ('renal dose') dopamine infusion can improve the
effectiveness of diuretic therapy, and help maintain renal func-
tion, although the evidence-base for this is limited. In our clinical
practice, this strategy is reserved for patients with systolic BP of
<100 mmHg without evidence of cardiogenic shock.
Mechanical ultraﬁltration can be used for the treatment of
ﬂuid retention and/or impaired diuretic responsiveness, but
further trials are required to identify which patients would
beneﬁt most from this treatment modality.
Conﬂicts of interest
The authors have none to declare.
r e f e r e n c e s
1. Cowie MR, Anker SD, Cleland JG, et al. Improving care for
patients with acute heart failure before, during and after
hospitalization. Oxford Health Policy Forum; 2014http://www.
oxfordhealthpolicyforum.org/reports/acute-heart-failure/
improving-care-for-patients-with-acute-heart-failure.
2. Maggioni AP, Dahlstrom U, Filippatos G, et al.
EURObservational Research Programme: the Heart Failure
Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12:1076–1084.
3. Maggioni AP, Dahlstrom U, Filippatos G, et al.
EURObservational Research Programme: regional
differences and 1-year follow-up results of the Heart Failure
Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15:808–817.
4. Testani JM, Brisco MA, Turner JM, et al. Loop diuretic
efﬁciency: a metric of diuretic responsiveness with
prognostic importance in acute decompensated heart
failure. Circ Heart Fail. 2014;7:261–270.
5. Valente MA, Voors AA, Damman K, et al. Diuretic response
in acute heart failure: clinical characteristics and prognostic
signiﬁcance. Eur Heart J. 2014;35:1284–1293.
6. Acute heart failure: diagnosing and managing acute heart failure
in adults. NICE guideline (CG187). 2014. https://www.nice.org.
uk/guidance/cg187.7. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on
cardiac, renal, and hepatic biomarkers in the Relaxin in
Acute Heart Failure (RELAX-AHF) development program:
correlation with outcomes. J Am Coll Cardiol. 2013;61:196–206.
8. Vazir A, Cowie MR. The use of diuretics in acute heart
failure: evidence based therapy? World J Cardiovasc Dis. 2013;
03:25–34.
9. Jessup M, Abraham WT, Casey DE, et al. 2009 focused
update: ACCF/AHA Guidelines for the Diagnosis and
Management of Heart Failure in Adults: a report of the
American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines: developed in
collaboration with the International Society for Heart and
Lung Transplantation. Circulation. 2009;119:1977–2016.
10. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines
for the diagnosis and treatment of acute and chronic heart
failure 2012: The Task Force for the Diagnosis and
Treatment of Acute and Chronic Heart Failure 2012 of the
European Society of Cardiology. Developed in collaboration
with the Heart Failure Association (HFA) of the ESC. Eur J
Heart Fail. 2012;14:803–869.
11. Vermeulen A, Chadha DR. Slow-release furosemide and
hydrochlorothiazide in congestive cardiac failure: a
controlled trial. J Clin Pharmacol. 1982;22:513–519.
12. Dargie HJ, Allison ME, Kennedy AC, et al. High dosage
metolazone in chronic renal failure. Br Med J. 1972;4:196–198.
13. Townsend HA, Waddy AL, Eason CT, et al. Frusemide/
amiloride combination ('Frumil') in heart failure: an open,
multi-centre study in general practice. Curr Med Res Opin.
1984;9:132–140.
14. Kohvakka A. Maintenance of potassium balance during
long-term diuretic therapy in chronic heart failure patients
with thiazide-induced hypokalemia: comparison of
potassium supplementation with potassium chloride and
potassium-sparing agents, amiloride and triamterene. Int J
Clin Pharmacol Ther Toxicol. 1988;26:273–277.
15. Kourouklis C, Christensen O, Augoustakis D. Bumetanide in
congestive heart failure. Curr Med Res Opin. 1976;4:422–431.
16. Patterson JH, Adams Jr KF, Applefeld MM, et al. Oral
torsemide in patients with chronic congestive heart failure:
effects on body weight, edema, and electrolyte excretion.
Torsemide Investigators Group. Pharmacotherapy.
1994;14:514–521.
17. Stewart JH, Edwards KD. Clinical comparison of frusemide
with bendroﬂuazide, mersalyl, and ethacrynic acid. Br Med J.
1965;2:1277–1281.
18. Faris R, Flather M, Purcell H, et al. Current evidence
supporting the role of diuretics in heart failure: a meta
analysis of randomised controlled trials. Int J Cardiol.
2002;82:149–158.
19. Crawford RJ, Allman S, Gibson W, et al. A comparative study
of frusemide-amiloride and cyclopenthiazide-potassium
chloride in the treatment of congestive cardiac failure in
general practice. J Int Med Res. 1988;16:143–149.
20. Gonska BD, Kreuzer H. [Diuretic monotherapy in heart
failure. Comparison of piretanide and hydrochlorothiazide-
triamterene]. Dtsch Med Wochenschr. 1985;110:1812–1816.
21. Funke Kupper AJ, Fintelman H, Huige MC, et al. Cross-over
comparison of the ﬁxed combination of hydrochlorothiazide
and triamterene and the free combination of furosemide and
triamterene in the maintenance treatment of congestive
heart failure. Eur J Clin Pharmacol. 1986;30:341–343.
22. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in
patients with acute decompensated heart failure. N Engl J
Med. 2011;364:797–805.
23. Paterna S, Fasullo S, Parrinello G, et al. Short-term effects of
hypertonic saline solution in acute heart failure and long-
term effects of a moderate sodium restriction in patients
with compensated heart failure with New York Heart
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 6 1 – s 6 8S68Association class III (Class C) (SMAC-HF Study). Am J Med Sci.
2011;342:27–37.
24. Tuttolomondo A, Pinto A, Parrinello G, et al. Intravenous high-
dose furosemide and hypertonic saline solutions for refractory
heart failure and ascites. Semin Nephrol. 2011;31:513–522.
25. Ravnan SL, Ravnan MC, Deedwania PC. Pharmacotherapy in
congestive heart failure: diuretic resistance and strategies to
overcome resistance in patients with congestive heart
failure. Congest Heart Fail. 2002;8:80–85.
26. Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic
resistance predicts mortality in patients with advanced
heart failure. Am Heart J. 2002;144:31–38.
27. Brater DC, Day B, Burdette A, et al. Bumetanide and
furosemide in heart failure. Kidney Int. 1984;26:183–189.
28. Vasko MR, Cartwright DB, Knochel JP, et al. Furosemide
absorption altered in decompensated congestive heart
failure. Ann Intern Med. 1985;102:314–318.
29. de Silva R, Nikitin NP, Witte KK, et al. Incidence of renal
dysfunction over 6 months in patients with chronic heart
failure due to left ventricular systolic dysfunction:
contributing factors and relationship to prognosis. Eur Heart
J. 2006;27:569–581.
30. Stanton BA, Kaissling B. Adaptation of distal tubule and
collecting duct to increased Na delivery. II. Na+ and K+
transport. Am J Physiol. 1988;255:F1269–F1275.
31. Kiyingi A, Field MJ, Pawsey CC, et al. Metolazone in
treatment of severe refractory congestive cardiac failure.
Lancet. 1990;335:29–31.
32. Sigurd B, Olesen KH, Wennevold A. The supra-additive
natriuretic effect addition of bendroﬂumethiazide and
bumetanide in congestive heart failure. Permutation trial
tests in patients in long-term treatment with bumetanide.
Am Heart J. 1975;89:163–170.
33. Bock JS, Gottlieb SS. Cardiorenal syndrome: new
perspectives. Circulation. 2010;121:2592–2600.
34. Elkayam U, Ng TM, Hatamizadeh P, et al. Renal vasodilatory
action of dopamine in patients with heart failure: magnitude
of effect and site of action. Circulation. 2008;117:200–205.
35. Triposkiadis FK, Butler J, Karayannis G, et al. Efﬁcacy and
safety of high dose versus low dose furosemide with or
without dopamine infusion: the Dopamine in Acute
Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol.
2014;172:115–121.
36. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose
dopamine or low-dose nesiritide in acute heart failure with
renal dysfunction: the ROSE acute heart failure randomized
trial. J Am Med Assoc. 2013;310:2533–2543.
37. Jaski BE, Ha J, Denys BG, et al. Peripherally inserted veno-
venous ultraﬁltration for rapid treatment of volume
overloaded patients. J Card Fail. 2003;9:227–231.38. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultraﬁltration
versus intravenous diuretics for patients hospitalized for
acute decompensated heart failure. J Am Coll Cardiol. 2007;
49:675–683.
39. Schroeder KL, Sallustio JE, Ross EA. Continuous haematocrit
monitoring during intradialytic hypotension: precipitous
decline in plasma reﬁll rates. Nephrol Dial Transplant.
2004;19:652–656.
40. Marenzi G, Lauri G, Grazi M, et al. Circulatory response to
ﬂuid overload removal by extracorporeal ultraﬁltration in
refractory congestive heart failure. J Am Coll Cardiol. 2001;
38:963–968.
41. Bart BA, Goldsmith SR, Lee KL, et al. Ultraﬁltration in
decompensated heart failure with cardiorenal syndrome. N
Engl J Med. 2012;367:2296–2304.
42. Konstam MA, Gheorghiade M, Burnett Jr JC et al. Effects of
oral tolvaptan in patients hospitalized for worsening heart
failure: the EVEREST Outcome Trial. J Am Med Assoc.
2007;297:1319–1331.
43. Gheorghiade M, Konstam MA, Burnett Jr JC et al. Short-
term clinical effects of tolvaptan, an oral vasopressin
antagonist, in patients hospitalized for heart failure: the
EVEREST Clinical Status Trials. J Am Med Assoc. 2007;297:
1332–1343.
44. Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an
adenosine A1-receptor antagonist, in acute heart failure. N
Engl J Med. 2010;363:1419–1428.
45. Liu C, Liu G, Zhou C, et al. Potent diuretic effects of
prednisone in heart failure patients with refractory diuretic
resistance. Can J Cardiol. 2007;23:865–868.
46. Liu C, Chen Y, Kang Y, et al. Glucocorticoids improve renal
responsiveness to atrial natriuretic peptide by up-regulating
natriuretic peptide receptor-A expression in the renal inner
medullary collecting duct in decompensated heart failure. J
Pharmacol Exp Ther. 2011;339:203–209.
47. Massari F, Mastropasqua F, Iacoviello M, et al. The
glucocorticoid in acute decompensated heart failure: Dr
Jekyll or Mr Hyde? Am J Emerg Med. 2012;30:517.e5–517.e10.
48. Liu C, Liu K, Group C-A. Cardiac outcome prevention
effectiveness of glucocorticoids in acute decompensated
heart failure: COPE-ADHF study. J Cardiovasc Pharmacol. 2014;
63:333–338.
49. Packer M, Colucci W, Fisher L, et al. Effect of
levosimendan on the short-term clinical course of
patients with acutely decompensated heart failure. JACC
Heart Fail. 2013;1:103–111.
50. Voors AA, Davison BA, Teerlink JR, et al. Diuretic response in
patients with acute decompensated heart failure:
characteristics and clinical outcome – an analysis from
RELAX-AHF. Eur J Heart Fail. 2014;16:1230–1240.
